The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 04, 2022

Filed:

Jul. 11, 2019
Applicants:

Maryam Mobed-miremadi, Sunnyvale, CA (US);

Chantell Farias, San Jose, CA (US);

Cecilia Hemingway, San Francisco, CA (US);

Roman Lyman, San Francisco, CA (US);

Inventors:

Maryam Mobed-Miremadi, Sunnyvale, CA (US);

Chantell Farias, San Jose, CA (US);

Cecilia Hemingway, San Francisco, CA (US);

Roman Lyman, San Francisco, CA (US);

Assignee:

Santa Clara University, Santa Clara, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 37/00 (2006.01); B33Y 80/00 (2015.01);
U.S. Cl.
CPC ...
A61M 37/0015 (2013.01); B33Y 80/00 (2014.12); A61M 2037/003 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0053 (2013.01); A61M 2209/02 (2013.01);
Abstract

A 3D printed biocompatible drug delivery device is provided having a fluid delivery channel distinguishing three segments and a receiving chamber with an array of microneedles. The three segments of the delivery channel are stagnation zones before a drug is extruded and whereby an inverted funnel provides an increasing extrusion surface servicing the drug to the array of microneedles. The design of the device with its flow-related components circumvents the challenge of colloidal stability associated with multi-phase formulations leading to nozzle blockage. Qualitative screening cytotoxicity tests pre and post-extrusion through the drug delivery device using mammalian cells rule out cytotoxicity and outline equivalent viability to control treatments. The biocompatibility results suggest that the fluid delivery design, the photoresin selected as well as the fabrication and sterilization may be extended over a range of regenerative medicine and drug delivery applications.


Find Patent Forward Citations

Loading…